News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
729,082 Results
Type
Article (41277)
Company Profile (310)
Press Release (687485)
Multimedia
Podcasts (80)
Webinars (17)
Section
Business (207037)
Career Advice (2035)
Deals (35852)
Drug Delivery (110)
Drug Development (82445)
Employer Resources (175)
FDA (16447)
Job Trends (15078)
News (350212)
Policy (32929)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2573)
Accelerated approval (31)
Adcomms (24)
Allergies (138)
Alliances (50230)
ALS (170)
Alzheimer's disease (1667)
Antibody-drug conjugate (ADC) (306)
Approvals (16719)
Artificial intelligence (508)
Autoimmune disease (149)
Automation (38)
Bankruptcy (361)
Best Places to Work (11737)
BIOSECURE Act (20)
Biosimilars (190)
Biotechnology (205)
Bladder cancer (158)
Brain cancer (56)
Breast cancer (636)
Cancer (4781)
Cardiovascular disease (407)
Career advice (1717)
Career pathing (35)
CAR-T (279)
CDC (44)
Celiac Disease (2)
Cell therapy (738)
Cervical cancer (36)
Clinical research (70403)
Collaboration (1700)
Company closure (4)
Compensation (1159)
Complete response letters (52)
COVID-19 (2719)
CRISPR (87)
C-suite (830)
Cystic fibrosis (145)
Data (6195)
Decentralized trials (2)
Denatured (25)
Depression (133)
Diabetes (497)
Diagnostics (6683)
Digital health (44)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (244)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (228)
Earnings (90986)
Editorial (56)
Employer branding (22)
Employer resources (153)
Events (119391)
Executive appointments (975)
FDA (19542)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1451)
Gene editing (192)
Generative AI (42)
Gene therapy (589)
GLP-1 (973)
Government (4668)
Grass and pollen (7)
Guidances (383)
Healthcare (18917)
HIV (56)
Huntington's disease (44)
IgA nephropathy (81)
Immunology and inflammation (244)
Immuno-oncology (54)
Indications (105)
Infectious disease (2978)
Inflammatory bowel disease (187)
Inflation Reduction Act (14)
Influenza (110)
Intellectual property (243)
Interviews (319)
IPO (16826)
IRA (49)
Job creations (3688)
Job search strategy (1436)
JPM (56)
Kidney cancer (15)
Labor market (83)
Layoffs (549)
Leadership (30)
Legal (7975)
Liver cancer (91)
Longevity (15)
Lung cancer (644)
Lymphoma (374)
Machine learning (42)
Management (59)
Manufacturing (784)
MASH (163)
Medical device (13765)
Medtech (13817)
Mergers & acquisitions (20094)
Metabolic disorders (1259)
Multiple sclerosis (163)
NASH (16)
Neurodegenerative disease (313)
Neuropsychiatric disorders (86)
Neuroscience (2893)
Neurotech (1)
NextGen: Class of 2026 (6546)
Non-profit (4523)
Now hiring (65)
Obesity (590)
Opinion (257)
Ovarian cancer (164)
Pain (199)
Pancreatic cancer (222)
Parkinson's disease (281)
Partnered (33)
Patents (490)
Patient recruitment (480)
Peanut (55)
People (59528)
Pharmaceutical (73)
Pharmacy benefit managers (29)
Phase 1 (21978)
Phase 2 (31034)
Phase 3 (23004)
Pipeline (5138)
Policy (278)
Postmarket research (2570)
Preclinical (9327)
Press Release (64)
Prostate cancer (234)
Psychedelics (47)
Radiopharmaceuticals (285)
Rare diseases (825)
Real estate (6043)
Recruiting (70)
Regulatory (24610)
Reports (51)
Research institute (2397)
Resumes & cover letters (351)
Rett syndrome (27)
RNA editing (16)
RSV (76)
Schizophrenia (148)
Series A (237)
Series B (186)
Service/supplier (11)
Sickle cell disease (95)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3658)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (84)
The Weekly (53)
Vaccines (992)
Venture capital (88)
Weight loss (378)
Women's health (87)
Worklife (18)
Date
Today (75)
Last 7 days (574)
Last 30 days (2054)
Last 365 days (30077)
2026 (2939)
2025 (30429)
2024 (35560)
2023 (40472)
2022 (51633)
2021 (56244)
2020 (54470)
2019 (46898)
2018 (35313)
2017 (32506)
2016 (31948)
2015 (38018)
2014 (31842)
2013 (26766)
2012 (28940)
2011 (29608)
2010 (27666)
Location
Africa (746)
Alabama (88)
Alaska (7)
Arizona (307)
Arkansas (14)
Asia (40171)
Australia (6518)
California (11209)
Canada (3267)
China (1120)
Colorado (476)
Connecticut (473)
Delaware (333)
Europe (87277)
Florida (1683)
Georgia (353)
Hawaii (3)
Idaho (61)
Illinois (854)
India (62)
Indiana (517)
Iowa (22)
Japan (422)
Kansas (125)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1380)
Massachusetts (8100)
Michigan (319)
Minnesota (625)
Mississippi (5)
Missouri (127)
Montana (31)
Nebraska (28)
Nevada (121)
New Hampshire (78)
New Jersey (2992)
New Mexico (29)
New York (2972)
North Carolina (1496)
North Dakota (8)
Northern California (5459)
Ohio (330)
Oklahoma (21)
Oregon (42)
Pennsylvania (2262)
Puerto Rico (23)
Rhode Island (47)
South America (1120)
South Carolina (65)
South Dakota (1)
Southern California (4360)
Tennessee (172)
Texas (1733)
United States (39930)
Utah (333)
Vermont (1)
Virginia (261)
Washington D.C. (81)
Washington State (930)
West Virginia (4)
Wisconsin (108)
Wyoming (2)
729,082 Results for "eiger biopharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split
Eiger BioPharmaceuticals, Inc. today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30.
January 4, 2024
·
5 min read
Deals
Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today announced that it and its direct subsidiaries have filed voluntary petitions for chapter 11 protection under the United States Bankruptcy Code in the United States Bankruptcy Court for the Northern District of Texas.
April 1, 2024
·
3 min read
Deals
Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals
Sentynl Therapeutics, Inc. (Sentynl) and Eiger BioPharmaceuticals, Inc. (OTC: EIGRQ), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced the closing of the sale of Eiger’s Zokinvy® (lonafarnib) program to Sentynl.
May 3, 2024
·
11 min read
Business
Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today reported financial results for the third quarter 2023 and provided a business update.
November 9, 2023
·
8 min read
Press Releases
Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors
February 2, 2026
·
3 min read
Business
Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today reported financial results for the second quarter 2023 and provided a business update.
August 14, 2023
·
8 min read
Biotech Bay
Eiger BioPharmaceuticals to Host Business Update Call Tomorrow
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) today announced that following an extensive portfolio prioritization exercise, the company will host a conference call and live webcast on Thursday, June 29, at 8:30 am ET.
June 28, 2023
·
1 min read
Biotech Bay
Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that David Apelian, MD, PhD, MBA, CEO of Eiger, will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023 at 7:00 AM ET in New York, NY.
September 5, 2023
·
1 min read
Deals
Eiger Files for Bankruptcy, Plans to Shutter Operations After Difficult Year
Following a series of rejections and clinical failures, Eiger BioPharmaceuticals has declared bankruptcy and will sell all its assets as the company winds down operations.
April 2, 2024
·
2 min read
·
Tristan Manalac
Mergers & Acquisitions
Amylyx Pivots to GLP-1 Space, Acquires Phase III-Ready Asset from Eiger
After pulling its ALS drug Relyvrio from the market, Amylyx Pharmaceuticals is looking to target the GLP-1 space with the purchase of Eiger BioPharmaceuticals’ avexitide, which has been studied for the treatment of hyperinsulinemic hypoglycemia.
July 10, 2024
·
2 min read
·
Tyler Patchen
1 of 72,909
Next
